Milena Gilestro

High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

Luca Bertamini, Stefania Oliva, Delia Rota‐Scalabrini et al. · Journal of Clinical Oncology · 2022 · 88 citations · Full text

Medicine, Hematology, Oncology +17

Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents

Vittorio Emanuele Muccio, Elona Saraci, Milena Gilestro et al. · Cytometry Part B Clinical Cytometry · 2015 · 54 citations · Full text

Medicine, Hematology, Oncology +17

Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial

Stefania Oliva, Davine Hofste op Bruinink, Lucie Říhová et al. · Blood Cancer Journal · 2021 · 47 citations · Full text

Medicine, Hematology, Oncology +17

Diagnostics in Waldenström’s macroglobulinemia: a consensus statement of the European Consortium for Waldenström’s Macroglobulinemia

Irene Dogliotti, Cristina Jiménez, Marzia Varettoni et al. · Leukemia · 2022 · 45 citations · Full text

Medicine, Hematology, Oncology +12

Minimal residual disease by flow cytometry and allelic‐specific oligonucleotide real‐time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis

Manuela Gambella, Paola Omedè, Stefano Spada et al. · Cancer · 2018 · 40 citations · Full text

Medicine, Hematology, Oncology +17